ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)
Proceeds support first-in-class development program through key clinical and regulatory milestones, including completion of the Phase 2 STAR trial in HIE, top-line data readout, and End-of-Phase 2 meeting with the FDA Company has raised more…